Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
Status:
Recruiting
Trial end date:
2022-05-17
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to assess the feasibility and the safety of the addition
of immunotherapy with PD-1 antibody nivolumab +/- CTLA-4 antibody ipilimumab to concomitant
chemoradiation therapy (CRT) in inoperable patients with early or locally advanced
oesophageal cancer and to select the more promising experimental arm among the two possible
combinations in terms of activity (based on progression free survival (PFS) at 12 months
according to RECIST 1.1) for further evaluation in a phase III trial.
The secondary objectives will aim to evaluate progression-free survival, failure-free
survival and overall survival and pattern of progression (including incidence of distance
metastasis).
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC